triglyceride concentrations of those samples. All concentrations represent duplicate determinations, with the difference between the single results being Յ5% in all cases. At triglyceride concentrations of ϳ3000 mg/L, the bias for HDL-cholesterol was close to 10%. At the highest concentration of ␤-VLDL, the triglycerides were 5710 mg/L and HDL-cholesterol was overestimated by Ͼ20%. The same experiment was performed with VLDL isolated from a patient with hypertriglyceridemia. This preparation contained 11 350 mg/L triglycerides and 2650 mg/L cholesterol. The maximal triglyceride concentration after the addition of ␤-VLDL to serum from a healthy donor as described above was 4600 mg/L. The HDL-cholesterol was determined to be 15 mg/L higher than in the sample to which only NaCl had been added, which is within the imprecision of the method. Overall, no systematic effect on the homogeneous HDL determination was observed in the range analyzed. These experiments confirm that VLDL from type III sera causes a positive bias when HDL-cholesterol is measured by the homogeneous method.
In summary, our results show that the presence of ␤-VLDL, as is typically seen in patients with type III hyperlipoproteinemia, interferes with the newly developed homogeneous HDL-cholesterol determination based on PEG-modified enzymes. In these patients, HDL-cholesterol will be overestimated at triglyceride concentrations far below 10 000 mg/L, which is within the range at which no triglyceride interference would be expected according to published data (7, 9) . The simplest explanation would be that the cholesterol associated with ␤-VLDL might be a substrate for these enzymes, although it reacts much less than HDL-cholesterol. However, because the concentration of ␤-VLDL, and thus ␤-VLDL-cholesterol, in type III patients is high, this leads to a positive bias when HDL-cholesterol is determined from whole serum. This finding could have further implications if one assumes that whole serum samples from other patients with abnormal VLDL or remnant particles, for example, diabetic patients, may cause similar problems in the homogeneous assay. To date, this has not been specifically investigated.
We gratefully acknowledge the expert technical assistance of Dieter Nutz, who brought this phenomenon to our attention.
Serum ␣-Fetoprotein in Newborns, Carlo Bellini, 1* Wanda Bonacci, 1 Enrico Parodi, 2 ␣-Fetoprotein (AFP) is a single chain ␣-globulin with a molecular weight of ϳ70 000. AFP is produced in the developing fetus by both the yolk sac and the fetal liver. At 12 weeks after conception the yolk sac degenerates and the fetal liver becomes the main site of synthesis. After 14 weeks of gestation (peak value of AFP), AFP synthesis decreases until parturition (1) . The observation that AFP synthesis does not entirely cease at birth may be explained on the basis of transient production sustained by the presence of fetal hepatocytes (1). Very few, contradictory, and incomplete data regarding the determination of reference values for AFP in healthy newborns, correlated to birth weight (BW) and/or gestational age (GA), are available (1) (2) (3) (4) (5) (6) (7) . Yet the usefulness of serum AFP as a diagnostic marker for the detection and/or differentiation of a great number of infantile diseases is well established, especially for some forms of malignant tumors and liver disorders (8, 9) .
Apparently healthy newborns (n ϭ 150; 71 males and 79 females) admitted to our Neonatal Intensive Care Unit (Servizio di Patologia Neonatale, Università di Genova, Italia) were included in the study. Single capillary blood specimens were collected with parental consent within 24 h of birth, when blood collection for other clinical testing was carried out. All subjects were delivered naturally. Subjects who were delivered by cesarean section were excluded from the study. No relevant perinatal complications were present, and no evidence of hepatobiliary disease, cardiac disease, severe respiratory distress, infection, or congenital malformations was found. Six babies with conditions that had been associated previously with abnormal maternal plasma AFP concentra-tions were excluded. Five infants who developed severe hyaline membrane disease had plasma AFP concentrations that were similar to those of babies of the same GA who did not have this complication. No babies were delivered from diabetic mothers. Dexamethasone treatment administrated to the mothers of four babies before delivery to accelerate lung maturation did not appear to have a major effect on the early postnatal AFP concentration. In spite of this, these last two groups of patients were excluded. Infants at 30 weeks of gestation and those who weighed 1500 g or less were included in the study only if they were free of severe respiratory distress syndrome.
GA was calculated by the mother's estimated date of last menstrual period, by fetal ultrasonic evaluation, and by physical examination after birth (Dubowitz scoring system).
Serum AFP concentrations were determined by double antibody radioimmunoassay (Serono ® ) with a detection limit of 2 g/L and an imprecision (CV) of 5.9% (18.6 Ϯ 1.1 g/L). The assay requires only 50 L of blood. Because most of the infant serum specimens contained much higher AFP concentrations than adult samples, proper dilution was required before the assay.
Conventional statistical methods were applied to calculate the mean and SD. The statistical significance of the difference between mean values of subpopulations was evaluated by the Student t-test, with a significance level defined at P ϭ 0.05. Differences in the means of multiple subpopulations were evaluated using ANOVA. Changes of AFP concentrations with GA and BW, the x and y variables representing AFP values in g/L, BW in grams (Fig. 1A) , and GA in weeks (Fig. 1B) , respectively, were evaluated by regression analysis; the regression equations are shown in Fig. 1 .
BW values correlated significantly with GA. On the basis of correlation analysis (r ϭ 0.76; P Ͻ0.001) the babies included in our study appeared to be of appropriate BW. No significant difference was found between AFP values in males vs females (males, n ϭ 71, AFP ϭ 151 Ϯ 61 mg/L; females, n ϭ 79, AFP ϭ 150 Ϯ 59 mg/L). There was significant correlation between AFP values and BW (r ϭ 0.39; P Ͻ0.001) and AFP and GA (r ϭ 0.49; P Ͻ0.001). Fig.  1 shows the regression of AFP concentration in our patients vs BW and GA, as calculated by the equation. The 95% confidence interval for each regression line is shown as dashed lines.
Several studies of AFP concentration in newborns have been carried out. Blair et al. (1) provided serum AFP reference values derived using logarithmic transformation of plasma AFP values and rearrangement against patient age corrected for GA deficit. Samples were obtained from 56 babies from birth to 5 months of age with various GAs. Serum AFP reference values in infancy were determined on the basis of mathematical correction of the data obtained.
Wu et al.
(2) evaluated average health-related serum AFP concentrations at various ages in 32 healthy babies generically split into two different groups, premature and newborn, without further indication regarding GA and/or BW.
Mizejewski and co-workers (3, 4) studied serum AFP concentrations in newborns partitioned in two subgroups to distinguish small-for-gestational age (2500 -2950 g) from premature (Ͻ2500 g) infants. The authors concluded that BW had to be considered the indicator of choice, whereas GA had to be avoided because its estimation was highly subjective. Goraya et al. (5) provided plasma AFP values in preterm neonates. The authors included patients enrolled in the study belonging to four different groups, according to different GA and BW. This methodology failed to take into account the GA and the BW of each patient. Reference values were referred to the individual groups.
Obiekwe et al. (6) compared maternal and fetal AFP concentrations at term; they did not consider preterm infants. In fact, the lowest GA included in the study was 36 weeks. In addition, subjects from 36 to 39 weeks were considered as one single group. Obiekwe et al. vided the sole observation regarding significant differences between AFP concentrations in males vs females, because AFP concentrations are considerably higher in males than in females.
Lee et al. (7) elaborated their data regarding serum AFP determination in a pediatric population ranging from newborn to children 12 months of age by using different and sophisticated statistical analysis. This study did not report definite values regarding GA and BW.
On the basis of these observations, we can conclude that, to date, reference values for AFP in healthy newborns at birth for both premature and full-term newborns are not well defined.
Our results demonstrate the following in our population: BW correlated significantly with GA; correlation analysis data (r ϭ 0.76; P Ͻ0.001) suggested that all babies included in the study were of appropriate BW; there was no significant difference between AFP concentrations in males vs females; and there was significant correlation between AFP concentrations and BW (r ϭ 0.39; P Ͻ0.001) and between AFP concentrations and GA (r ϭ 0.49; P Ͻ0.001).
We conclude that the regression curves shown in Fig. 1 , which relate AFP concentrations with BW and GA, may be used as a frame of reference to assist the interpretation of AFP concentrations in newborn infants. Furosemide is a commonly used diuretic available in both oral and intravenous formulations. Furosemide is a known inhibitor of thyroid hormone binding in serum (1) , and high-dose treatment with furosemide can lower total thyroxine and increase its free fraction in vivo (2) . The difficulty in assessing thyroid status in severe illness is well known (3) , and this difficulty can be complicated by treatment with drugs such as furosemide. The following study was undertaken after investigation of a patient in the coronary care unit with a thyroid-stimulating hormone (TSH) concentration within the health-related reference interval coupled with a free thyroxine of Ͼ77 pmol/L on the Abbott AxSYM immunoassay analyzer (reference interval, 9 -24 pmol/L). In a subsequent sample, the free thyroxine was 16.2 pmol/L. The error was attributed to contamination of the sample by intravenous furosemide. I investigated the effects of furosemide on the measurement of free thyroxine and TSH, using three different assay systems: the AxSYM from Abbott Laboratories, the ACS:180 from Chiron, and the Vitros from Ortho Clinical Diagnostics.
Furosemide Interference in Newer Free Thyroxine As
An intravenous formulation of furosemide (28.5 mmol/L) from Hoechst Laboratories was diluted with serum from a pool of euthyroid individuals to produce eight samples with dilution factors ranging from 100 to 6000. The serum pools and all diluted samples were analyzed for both free thyroxine and TSH, using the Abbott AxSYM, the Chiron ACS:180, and the Ortho Vitros. The Abbott AxSYM uses microparticle enzyme immunoassay technology, whereas the Chiron ACS:180 and the Ortho Vitros use chemiluminescent assay systems. The sample volume:total volume ratios for the free thyroxine assays were as follows: Vitros, 0.20; AxSYM, 0.11; and ACS:180, 0.04. All results were compared with those from the serum pool and displayed as the percentage of change in analyte concentration.
The relative effects of furosemide contamination on free thyroxine in serum are shown in Fig. 1 . The Ortho Vitros assay was most affected, whereas the ACS:180 assay showed the least interference from the presence of furosemide. Assay sensitivity to furosemide increased with increasing sample volume:total volume ratios. I found no significant change in measured TSH concentration with any furosemide dilution in any assay (data not shown).
The interference of furosemide with free thyroxine assays should further discourage sampling for thyroid tests from 
